Economic evaluations of telepharmacy services in non-cancer settings: A systematic review

Res Social Adm Pharm. 2024 Mar;20(3):246-254. doi: 10.1016/j.sapharm.2024.01.002. Epub 2024 Jan 5.

Abstract

Background: Telepharmacy is the provision of pharmacy services from a distance to a patient using telecommunications and other technologies. There has been limited research investigating the cost-effectiveness of telepharmacy services.

Objective: To provide a comprehensive review and narrative synthesis of the available economic evidence on telepharmacy services in non-cancer settings.

Method: A systematic literature search of four databases including PubMed, Embase, CINAHL, and EconLit was undertaken to identify economic evaluations comparing telepharmacy services to standard pharmacy care. Abstracts and full texts were screened by two independent reviewers for inclusion against the eligibility criteria. Key economic findings were extracted from included articles to determine the cost-effectiveness of the reported telepharmacy services.

Results: The review included six studies; two were cost-minimisation analyses, three were cost effectiveness analyses (CEA) and one study conducted both a CEA and cost-utility analysis. Telepharmacy services predominantly relied upon telephone modes of communication, with three that used remote patient monitoring. These services managed a variety of clinical situations which included newly initiated antibiotics, antiretroviral therapy management, and medications for chronic conditions, as well as hypertension management. Articles were of relatively high reporting quality, scoring an average of 83% on the Consolidated Health Economics Reporting Standards checklist. Four of the six studies reported that telepharmacy was less costly than usual care, with two that reported telepharmacy as cost-effective to the healthcare system according to a specified cost-effectiveness threshold.

Conclusions: Overall, this review demonstrates that there is emerging evidence that telepharmacy services can be cost-effective compared with standard care in non-cancer settings. Further research is needed to complement these findings, particularly reflecting the increased uptake of telehealth and telepharmacy services since the onset of the Coronavirus disease pandemic.

Keywords: Cost; Economics; Pharmacy; Telehealth; Telemedicine; Telepharmacy.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Cost-Benefit Analysis
  • Humans
  • Hypertension*
  • Pharmaceutical Services*
  • Telemedicine*